Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Tarsus Pharmaceuticals Inc maintains a gross margin of 93.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -12.24%, while the net margin is -10.60%. These profitability ratios, combined with a Return on Equity (ROE) of -28.35%, provide a clear picture of how effectively TARS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TARS competes directly with industry leaders such as CPRX and ERAS. With a market capitalization of $2.73B, it holds a significant position in the sector. When comparing efficiency, TARS's gross margin of 93.00% stands against CPRX's 78.44% and ERAS's N/A. Such benchmarking helps identify whether Tarsus Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
